Global Esketamine Nasal Spray Market

Esketamine Nasal Spray Comprehensive Study by Application (General Anesthetics, Treatment-Resistant Depression), End Use (Hospitals, Specialty Clinics), End User (Pediatric, Adults, Geriatric) Players and Region - Global Market Outlook to 2030

Esketamine Nasal Spray Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Esketamine Nasal Spray
Treatment-resistant depression (TRD); depression that may not change with treatment in adults is managed with Esketamine nasal spray in conjunction with another antidepressant taken orally. The dose and recovery plan are determined by your current diagnosis and treatment reaction. TRD is characterized as major depressive disorder (MDD) in adults who have failed to respond to at least two antidepressant medications during their current mild to extreme depressive episode. The nasal spray Esketamine is sometimes used as a general anesthetic. During the entire therapy session, the drug is delivered under the close supervision of a healthcare provider. Due to misuse and malpractices the drug is one of the highly regulated in specific regions. The Esketamine Nasal Spray market is set to attract huge demand due to multiple factors including rising number of depression related suicide cases.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Esketamine Nasal Spray market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck Group (Germany), Medkoo (United States), Endo International (Ireland), Janssen Pharmaceutica (Johnson & Johnson) (Belgium), Pfizer (United States), Karuna Therapeutics (United States), Bayer AG (Germany) and Viatris (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sinopharm (China), Humanwell Pharmaceutical (China) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Esketamine Nasal Spray market by , Application (General Anesthetics and Treatment-Resistant Depression) and Region.



On the basis of geography, the market of Esketamine Nasal Spray has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Hospitals will boost the Esketamine Nasal Spray market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Pediatric will boost the Esketamine Nasal Spray market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Mental Health Awareness

Market Growth Drivers:
Surge Depression Related Suicide Cases Among Young and Adults

Challenges:
Regional Regulatory Approval and To Provide for Rising Demand

Restraints:
Adverse Side Effects Such as Sedation and dissociation and Misuse and Drug Abuse

Opportunities:
Unexplored Markets and Growth in Healthcare Infrastructure

Market Leaders and their expansionary development strategies
In December, 2019 - Janssen Pharmaceutica’s Esketamine Nasal Spray “Spravato” in Combination with an Oral Antidepressant Received Regulatory Clearance from European Commission for Sale Across European Union. The Approval Was Based on The Results of Five Phase III Trials.
In March, 2019 - Janssen Pharmaceutica’s Esketamine Nasal Spray “Spravato” was Approved by FDA For Treatment-Resistant Depression. Due to Abuse and Misuse the Drug/Spray will on Available on Medication Through a Restricted Distribution System, Under A Risk Evaluation and Mitigation Strategy (REM).
United States, Food and Drug Administration; USDA is the key Regulatory Authority Responsible for Approval, Inspection and Dosage Limitations of Esketamine Nasal Spray across the United States, FDA has Approved Products Including SPRAVATO. Any New Entrant is Required to have a Regulatory Clearance form FDA.

Key Target Audience
Esketamine Nasal Spray Manufactures, New Entrants and Investors, Esketamine Nasal Spray Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • General Anesthetics
  • Treatment-Resistant Depression
By End Use
  • Hospitals
  • Specialty Clinics

By End User
  • Pediatric
  • Adults
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surge Depression Related Suicide Cases Among Young and Adults
    • 3.3. Market Challenges
      • 3.3.1. Regional Regulatory Approval
      • 3.3.2. To Provide for Rising Demand
    • 3.4. Market Trends
      • 3.4.1. Growing Mental Health Awareness
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Esketamine Nasal Spray, by Application, End Use, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Esketamine Nasal Spray (Value)
      • 5.2.1. Global Esketamine Nasal Spray by: Application (Value)
        • 5.2.1.1. General Anesthetics
        • 5.2.1.2. Treatment-Resistant Depression
      • 5.2.2. Global Esketamine Nasal Spray by: End Use (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Clinics
      • 5.2.3. Global Esketamine Nasal Spray by: End User (Value)
        • 5.2.3.1. Pediatric
        • 5.2.3.2. Adults
        • 5.2.3.3. Geriatric
      • 5.2.4. Global Esketamine Nasal Spray Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Esketamine Nasal Spray: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck Group (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medkoo (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Endo International (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Janssen Pharmaceutica (Johnson & Johnson) (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Karuna Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Viatris (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Esketamine Nasal Spray Sale, by Application, End Use, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Esketamine Nasal Spray (Value)
      • 7.2.1. Global Esketamine Nasal Spray by: Application (Value)
        • 7.2.1.1. General Anesthetics
        • 7.2.1.2. Treatment-Resistant Depression
      • 7.2.2. Global Esketamine Nasal Spray by: End Use (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Clinics
      • 7.2.3. Global Esketamine Nasal Spray by: End User (Value)
        • 7.2.3.1. Pediatric
        • 7.2.3.2. Adults
        • 7.2.3.3. Geriatric
      • 7.2.4. Global Esketamine Nasal Spray Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Esketamine Nasal Spray: by Application(USD Million)
  • Table 2. Esketamine Nasal Spray General Anesthetics , by Region USD Million (2018-2023)
  • Table 3. Esketamine Nasal Spray Treatment-Resistant Depression , by Region USD Million (2018-2023)
  • Table 4. Esketamine Nasal Spray: by End Use(USD Million)
  • Table 5. Esketamine Nasal Spray Hospitals , by Region USD Million (2018-2023)
  • Table 6. Esketamine Nasal Spray Specialty Clinics , by Region USD Million (2018-2023)
  • Table 7. Esketamine Nasal Spray: by End User(USD Million)
  • Table 8. Esketamine Nasal Spray Pediatric , by Region USD Million (2018-2023)
  • Table 9. Esketamine Nasal Spray Adults , by Region USD Million (2018-2023)
  • Table 10. Esketamine Nasal Spray Geriatric , by Region USD Million (2018-2023)
  • Table 11. South America Esketamine Nasal Spray, by Country USD Million (2018-2023)
  • Table 12. South America Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 13. South America Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 14. South America Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 15. Brazil Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 16. Brazil Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 17. Brazil Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 18. Argentina Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 19. Argentina Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 20. Argentina Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 21. Rest of South America Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 22. Rest of South America Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 23. Rest of South America Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 24. Asia Pacific Esketamine Nasal Spray, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 26. Asia Pacific Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 27. Asia Pacific Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 28. China Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 29. China Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 30. China Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 31. Japan Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 32. Japan Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 33. Japan Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 34. India Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 35. India Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 36. India Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 37. South Korea Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 38. South Korea Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 39. South Korea Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 40. Taiwan Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 41. Taiwan Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 42. Taiwan Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 43. Australia Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 44. Australia Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 45. Australia Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 49. Europe Esketamine Nasal Spray, by Country USD Million (2018-2023)
  • Table 50. Europe Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 51. Europe Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 52. Europe Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 53. Germany Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 54. Germany Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 55. Germany Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 56. France Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 57. France Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 58. France Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 59. Italy Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 60. Italy Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 61. Italy Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 62. United Kingdom Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 63. United Kingdom Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 64. United Kingdom Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 65. Netherlands Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 66. Netherlands Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 67. Netherlands Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 68. Rest of Europe Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 69. Rest of Europe Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 70. Rest of Europe Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 71. MEA Esketamine Nasal Spray, by Country USD Million (2018-2023)
  • Table 72. MEA Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 73. MEA Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 74. MEA Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 75. Middle East Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 76. Middle East Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 77. Middle East Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 78. Africa Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 79. Africa Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 80. Africa Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 81. North America Esketamine Nasal Spray, by Country USD Million (2018-2023)
  • Table 82. North America Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 83. North America Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 84. North America Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 85. United States Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 86. United States Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 87. United States Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 88. Canada Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 89. Canada Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 90. Canada Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 91. Mexico Esketamine Nasal Spray, by Application USD Million (2018-2023)
  • Table 92. Mexico Esketamine Nasal Spray, by End Use USD Million (2018-2023)
  • Table 93. Mexico Esketamine Nasal Spray, by End User USD Million (2018-2023)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Esketamine Nasal Spray: by Application(USD Million)
  • Table 103. Esketamine Nasal Spray General Anesthetics , by Region USD Million (2025-2030)
  • Table 104. Esketamine Nasal Spray Treatment-Resistant Depression , by Region USD Million (2025-2030)
  • Table 105. Esketamine Nasal Spray: by End Use(USD Million)
  • Table 106. Esketamine Nasal Spray Hospitals , by Region USD Million (2025-2030)
  • Table 107. Esketamine Nasal Spray Specialty Clinics , by Region USD Million (2025-2030)
  • Table 108. Esketamine Nasal Spray: by End User(USD Million)
  • Table 109. Esketamine Nasal Spray Pediatric , by Region USD Million (2025-2030)
  • Table 110. Esketamine Nasal Spray Adults , by Region USD Million (2025-2030)
  • Table 111. Esketamine Nasal Spray Geriatric , by Region USD Million (2025-2030)
  • Table 112. South America Esketamine Nasal Spray, by Country USD Million (2025-2030)
  • Table 113. South America Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 114. South America Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 115. South America Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 116. Brazil Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 117. Brazil Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 118. Brazil Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 119. Argentina Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 120. Argentina Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 121. Argentina Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 122. Rest of South America Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 123. Rest of South America Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 124. Rest of South America Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 125. Asia Pacific Esketamine Nasal Spray, by Country USD Million (2025-2030)
  • Table 126. Asia Pacific Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 127. Asia Pacific Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 128. Asia Pacific Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 129. China Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 130. China Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 131. China Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 132. Japan Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 133. Japan Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 134. Japan Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 135. India Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 136. India Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 137. India Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 138. South Korea Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 139. South Korea Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 140. South Korea Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 141. Taiwan Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 142. Taiwan Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 143. Taiwan Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 144. Australia Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 145. Australia Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 146. Australia Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 147. Rest of Asia-Pacific Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 148. Rest of Asia-Pacific Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 150. Europe Esketamine Nasal Spray, by Country USD Million (2025-2030)
  • Table 151. Europe Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 152. Europe Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 153. Europe Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 154. Germany Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 155. Germany Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 156. Germany Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 157. France Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 158. France Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 159. France Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 160. Italy Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 161. Italy Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 162. Italy Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 163. United Kingdom Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 164. United Kingdom Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 165. United Kingdom Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 166. Netherlands Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 167. Netherlands Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 168. Netherlands Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 169. Rest of Europe Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 170. Rest of Europe Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 171. Rest of Europe Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 172. MEA Esketamine Nasal Spray, by Country USD Million (2025-2030)
  • Table 173. MEA Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 174. MEA Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 175. MEA Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 176. Middle East Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 177. Middle East Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 178. Middle East Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 179. Africa Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 180. Africa Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 181. Africa Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 182. North America Esketamine Nasal Spray, by Country USD Million (2025-2030)
  • Table 183. North America Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 184. North America Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 185. North America Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 186. United States Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 187. United States Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 188. United States Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 189. Canada Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 190. Canada Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 191. Canada Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 192. Mexico Esketamine Nasal Spray, by Application USD Million (2025-2030)
  • Table 193. Mexico Esketamine Nasal Spray, by End Use USD Million (2025-2030)
  • Table 194. Mexico Esketamine Nasal Spray, by End User USD Million (2025-2030)
  • Table 195. Research Programs/Design for This Report
  • Table 196. Key Data Information from Secondary Sources
  • Table 197. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Esketamine Nasal Spray: by Application USD Million (2018-2023)
  • Figure 5. Global Esketamine Nasal Spray: by End Use USD Million (2018-2023)
  • Figure 6. Global Esketamine Nasal Spray: by End User USD Million (2018-2023)
  • Figure 7. South America Esketamine Nasal Spray Share (%), by Country
  • Figure 8. Asia Pacific Esketamine Nasal Spray Share (%), by Country
  • Figure 9. Europe Esketamine Nasal Spray Share (%), by Country
  • Figure 10. MEA Esketamine Nasal Spray Share (%), by Country
  • Figure 11. North America Esketamine Nasal Spray Share (%), by Country
  • Figure 12. Global Esketamine Nasal Spray share by Players 2023 (%)
  • Figure 13. Global Esketamine Nasal Spray share by Players (Top 3) 2023(%)
  • Figure 14. Global Esketamine Nasal Spray share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Merck Group (Germany) Revenue: by Geography 2023
  • Figure 18. Medkoo (United States) Revenue, Net Income and Gross profit
  • Figure 19. Medkoo (United States) Revenue: by Geography 2023
  • Figure 20. Endo International (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Endo International (Ireland) Revenue: by Geography 2023
  • Figure 22. Janssen Pharmaceutica (Johnson & Johnson) (Belgium) Revenue, Net Income and Gross profit
  • Figure 23. Janssen Pharmaceutica (Johnson & Johnson) (Belgium) Revenue: by Geography 2023
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2023
  • Figure 26. Karuna Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 27. Karuna Therapeutics (United States) Revenue: by Geography 2023
  • Figure 28. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 30. Viatris (United States) Revenue, Net Income and Gross profit
  • Figure 31. Viatris (United States) Revenue: by Geography 2023
  • Figure 32. Global Esketamine Nasal Spray: by Application USD Million (2025-2030)
  • Figure 33. Global Esketamine Nasal Spray: by End Use USD Million (2025-2030)
  • Figure 34. Global Esketamine Nasal Spray: by End User USD Million (2025-2030)
  • Figure 35. South America Esketamine Nasal Spray Share (%), by Country
  • Figure 36. Asia Pacific Esketamine Nasal Spray Share (%), by Country
  • Figure 37. Europe Esketamine Nasal Spray Share (%), by Country
  • Figure 38. MEA Esketamine Nasal Spray Share (%), by Country
  • Figure 39. North America Esketamine Nasal Spray Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck Group (Germany)
  • Medkoo (United States)
  • Endo International (Ireland)
  • Janssen Pharmaceutica (Johnson & Johnson) (Belgium)
  • Pfizer (United States)
  • Karuna Therapeutics (United States)
  • Bayer AG (Germany)
  • Viatris (United States)
Additional players considered in the study are as follows:
Sinopharm (China) , Humanwell Pharmaceutical (China) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 218 Pages 77 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Esketamine Nasal Spray Market Quantitative research analysis
Global Esketamine Nasal Spray Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck Group (Germany), Medkoo (United States), Endo International (Ireland), Janssen Pharmaceutica (Johnson & Johnson) (Belgium), Pfizer (United States), Karuna Therapeutics (United States), Bayer AG (Germany) and Viatris (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Mental Health Awareness" is seen as one of major influencing trends for Esketamine Nasal Spray Market during projected period 2023-2030.
The Esketamine Nasal Spray market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Esketamine Nasal Spray Market Report?

Have a Query? Click Here

Other Related Reports

Allergy Shots Comprehensive Study by Application (Allergic Asthma, Allergic Rhinitis, Eye Allergies (or) Recurring Conjunctivitis, Other), Therapy (Sublingual Immunotherapy, Subcutaneous Immunotherap...
$ 3750
Real Time PCR qPCR Comprehensive Study by Type (Real-Time PCR (qPCR) Systems, Reagents and Assays, Consumables, PCR Primers, Reagents, PCR Plates, Others), Application (Gene expression (mRNA) analysi...
$ 3750
Antimicrobial Hospital Curtains Comprehensive Study by Application (Hospitals, Ambulatory surgical centers, Private clinics, Emergency Centers, Nursing homes), Usage (Reusable, Disposable/Single Use)...
$ 3350
Optogenetics Actuators And Sensors Comprehensive Study by Type (Actuators (Channelrhodopsin, Halorhodopsin, and Archaerhodopsin), Sensors (Genetically Encoded Calcium Indicators, Voltage-Sensitive Fl...
$ 3750
Medical oxygen concentrators and oxygen cylinders Comprehensive Study by Type (Portable medical oxygen concentrators, Stationary medical oxygen concentrators, Oxygen cylinders), Application (Copd, As...
$ 3650
Nasal Tube Fastener Comprehensive Study by Type (Latex, Fabric, Other), Application (Hospitals, Clinics, Others), Packaging (Box, Case), End User (Infant, Pediatric, Adult) Players and Region - Globa...
$ 3600